TLR4 and infection: Interestingly, a series of mild non-toxic agonists of TLR4 such as MPLA, have been proved to enhance host defense against infection via macrophage phagocytosis, and reduce systemic inflammation (Fensterheim et al., 2018; Hernandez et al., 2019).